Stay updated on Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Sign up to get notified when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.

Latest updates to the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page
- ChecktodayChange DetectedThe Taiwan site entry was updated from Taoyuan, Taiwan, 333 to Taoyuan City, Taiwan, 333, clarifying the exact city for this enrollment site. This change improves precision in the study's location listing for Taiwan.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page’s displayed revision/version footer was updated from **v3.5.2** to **v3.5.3**.SummaryDifference0.0%

- Check22 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check43 days agoChange DetectedNew study sites were added (Columbus, OH; Rabin Medical Center in Israel; Hospital Universitario Vall de Hebron in Spain) and some existing site identifiers were updated.SummaryDifference0.6%

- Check51 days agoChange DetectedRevision updated to v3.5.0 and the previous revision v3.4.3 was removed.SummaryDifference0.0%

- Check58 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a general site version update with no visible changes to study content or navigation.SummaryDifference0.0%

Stay in the know with updates to Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.